九州大学-研究者情報 [細川和也 (准教授) 先端医療オープンイノベーションセンター ]

細川和也（ほそかわかずや）

データ更新日：2024.04.09

准教授　／　先端医療オープンイノベーションセンター

学会発表等

1.	Kazuya Hosokawa　and Kohtaro Abe on behalf of CTEPH AC registry and KABUKI trial investigators, Seeking positioning of direct oral anticoagulants for the treatment of CTEPH, 第87回　日本循環器学会学術集会, 2023.03, CTEPH is a complication of preceding pulmonary thromboembolism (PE) and develops in approximately 4% of patients with PE. Although the pivotal pathogenesis of CTEPH is incomplete clot dissolution, once CTEPH is established, secondary pathogenic mechanisms including shear stress-induced microvascular arteriopathy in non-obstructed vascular areas and in situ thrombus formation due to blood flow disturbance cause disease progression. The consensus among experts is that patients with established CTEPH should receive indefinite anticoagulation therapy. Vitamin K antagonists (VKAs) have been widely used in this patient population. However, there has been an increase in use of direct oral anticoagulants (DOACs) in CTEPH patients as indicated by data from clinical trials in patients with venous thromboembolism. While DOACs are now established as first-line oral anticoagulants in patients following acute pulmonary embolism, their role in patients with CTEPH remains controversial. The Japanese investigators: CTEPH AC registry and KABUKI trial, are seeking to establish the positioning of direct oral anticoagulation for the treatment of CTEPH. The CTEPH AC registry is a nationwide registry started on August 20, 2018, in Japan. The current study is the first results, which was pre-specified in the protocol, of this prospective uncontrolled, non-interventional nationwide research aiming to compare the long-term safety and efficacy between DOACs and VKAs for the treatment of CTEPH. The KABUKI trial is randomized parallel group controlled non-inferiority trial sought to evaluate whether edoxaban, a direct factor Xa inhibitor, was non-inferior to warfarin in preventing worsening of CTEPH. The speakers on behalf of those investigators present future direction of DOACs for the treatment of CTEPH..
2.	細川和也, 要望演題3「慢性血栓塞栓性肺高血圧症における DOAC の使用状況とリスクベネフィット」単施設レジストリからみる慢性血栓塞栓性肺高血圧症におけるDOACの有効性と安全性 , 第28回肺塞栓症研究会学術集会, 2022.06.
3.	細川　和也, パネルディスカッション「右心機能と呼吸機能の生理学　基礎から検査法の意義と限界まで」肺高血圧症における心エコー、右心カテーテル検査の役割（基本＋α）, 2020.09.
4.	Kazuya Hosokawa, Kohtaro Abe, Hiroyuki Tsutsui, シンポジウム「Progress in CTEPH Treatment」 The Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with CTEPH, 第84回日本循環器学会学術集会（2020年7月27日～8月2日、京都）, 2020.07.
5.	Kazuya Hosokawa, Kouta Funakoshi, Atsushi Tanaka, takafumi sakamoto, Ken Onitsuka, Kazuo Sakamoto, Tomoyuki Tobushi, Takeo Fujino, Keita Saku, Yoshinori Murayama, Tomomi Ide, Kenji Sunagawa, Artificial baroreflex system restores volume tolerance in the absence of native baroreflex, 33rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society, EMBS 2011, 2011.12, [URL], The arterial baroreflex stabilizes arterial pressure by modulating the mechanical properties of cardiovascular system. We previously demonstrated that the baroreflex impairment makes the circulatory system extremely sensitive to volume overload and predisposes to pulmonary edema irrespective of left ventricular systolic function. To overcome the volume intolerance, we developed an artificial baroreflex system by directly stimulating the carotid sinus nerves in response to changes in arterial pressure. The artificial baroreflex system precisely reproduced the native arterial pressure response and restored physiological volume buffering function. We conclude that the artificial baroreflex system would be an attractive tool in preventing pulmonary edema in patients with impaired baroreflex function..
6.	Kazuya Hosokawa, Kohtaro Abe, Hiroyuki Tsutsui, Direct Oral Anticoagulants Shows Comparable Event Rate for Thromboembolism And Major Bleeding to Vitamin K Antagonist in Chronic Thromboembolic Pulmonary Hypertension, 第82回日本循環器学会総会学術集会, 2019.06.
7.	takafumi sakamoto, Yoshinori Murayama, Atsushi Tanaka, Kazuo Sakamoto, Tomoyuki Tobushi, Keita Saku, Kazuya Hosokawa, Ken Onitsuka, Takeo Fujino, Kenji Sunagawa, Impact of baroreflex on venous return surface, 33rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society, EMBS 2011, 2011.12, [URL], Background: Although Guyton's concept of venous return (VR) revolutionized circulatory physiology, the pulmonary circulation is invisible in its original framework. Since the pulmonary circulation is critical in left heart failure, we characterized the VR as a surface described by right (P _RA) and left atrial (P _LA) pressures and demonstrated that the VR surface was capable of representing mechanics of pulmonary as well as systemic circulation. However how baroreflex impacts the VR surface remains unknown. Methods/Results: In 8 dogs, we isolated the carotid sinuses and replaced both ventricles with pumps. We varied cardiac output, shifted blood distribution between the systemic and pulmonary circulation at carotid sinus pressures (CSP) of 100 or 140 mmHg. The coefficient of determination of the VR surface ranged 0.96-0.99 indicating how flat the surface is. Increasing CSP decreased maximum VR (23327 vs. 21633 ml/kg/min, p0.05), whereas did not change the slopes of VR along P _RA or P _LA axes. Conclusions: Baroreflex parallel shifts the VR surface, thereby stressed volume, without changing its slopes..
8.	Kazuya Hosokawa, Kouta Funakoshi, Atsushi Tanaka, takafumi sakamoto, Ken Onitsuka, Kazuo Sakamoto, Tomoyuki Tobushi, Takeo Fujino, Keita Saku, Yoshinori Murayama, Tomomi Ide, Kenji Sunagawa, Artificial baroreflex system restores volume tolerance in the absence of native baroreflex, 33rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society, EMBS 2011, 2011.12, [URL], The arterial baroreflex stabilizes arterial pressure by modulating the mechanical properties of cardiovascular system. We previously demonstrated that the baroreflex impairment makes the circulatory system extremely sensitive to volume overload and predisposes to pulmonary edema irrespective of left ventricular systolic function. To overcome the volume intolerance, we developed an artificial baroreflex system by directly stimulating the carotid sinus nerves in response to changes in arterial pressure. The artificial baroreflex system precisely reproduced the native arterial pressure response and restored physiological volume buffering function. We conclude that the artificial baroreflex system would be an attractive tool in preventing pulmonary edema in patients with impaired baroreflex function..
9.	Kazuya Hosokawa, Kouta Funakoshi, Atsushi Tanaka, takafumi sakamoto, Ken Onitsuka, Kazuo Sakamoto, Tomoyuki Tobushi, Takeo Fujino, Keita Saku, Yoshinori Murayama, Tomomi Ide, Kenji Sunagawa, Artificial baroreflex system restores volume tolerance in the absence of native baroreflex, 33rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society, EMBS 2011, 2011.12, [URL], The arterial baroreflex stabilizes arterial pressure by modulating the mechanical properties of cardiovascular system. We previously demonstrated that the baroreflex impairment makes the circulatory system extremely sensitive to volume overload and predisposes to pulmonary edema irrespective of left ventricular systolic function. To overcome the volume intolerance, we developed an artificial baroreflex system by directly stimulating the carotid sinus nerves in response to changes in arterial pressure. The artificial baroreflex system precisely reproduced the native arterial pressure response and restored physiological volume buffering function. We conclude that the artificial baroreflex system would be an attractive tool in preventing pulmonary edema in patients with impaired baroreflex function..

本データベースの内容を無断転載することを禁止します。

九大関連コンテンツ

pure2017年10月2日から、「九州大学研究者情報」を補完するデータベースとして、Elsevier社の「Pure」による研究業績の公開を開始しました。

　

QIR　九州大学学術情報リポジトリシステム情報科学研究院

九州大学病院